EndoChoice (GI) IPO Opens Modestly Lower

Today's IPO for EndoChoice (NYSE: GI) opened for trading at $14.50 after pricing 6,350,000 shares of its common stock at a price to the public of $15.00 per share.

J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering. William Blair and Stifel are acting as co-managers for the offering.

Based in the Atlanta, Georgia area, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists screening, diagnosing and treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 25 countries. The Company was founded in 2008 and has developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy® System (Fuse®).

You May Also Be Interested In

• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• Dentsply Sirona names John Fortson as chief financial officer
• Apotex debut delivers rare IPO boost to Canada’s equity market